(9-hydroxy-7,8,9,10-tetrahydro-pyrido[2,1-a]isoindol-6-yl)-acetic acid ethyl ester | 1236035-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (9-hydroxy-7,8,9,10-tetrahydro-pyrido[2,1-a]isoindol-6-yl)-acetic acid ethyl ester
• 英文别名: (9-Hydroxy-7,8,9,10-tetrahydro-pyrido[2,1-a] isoindol-6-yl)-acetic acid ethyl ester；ethyl 2-(9-hydroxy-7,8,9,10-tetrahydropyrido[1,2-b]isoindol-6-yl)acetate
• CAS: 1236035-13-4
• 化学式: C₁₆H₁₉NO₃
• 分子量: 273.332
• InChiKey: NUTHVJVVHFUDAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (9-hydroxy-7,8,9,10-tetrahydro-pyrido[2,1-a]isoindol-6-yl)-acetic acid ethyl ester 、 甲基磺酰氯 生成 (9-methanesulfonyloxy-7,8,9,10-tetrahydro-pyrido[2,1-a]isoindol-6-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

  摘要：

  本文描述了PGD2受体拮抗剂。还描述了包括本文所述化合物的制药组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症。

  公开号：

  US20120004233A1
• 作为产物：
  描述：

  (9-oxo-7,8,9,10-tetrahydro-pyrido[2,1-a]isoindol-6-yl)-acetic acid ethyl ester 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成 (9-hydroxy-7,8,9,10-tetrahydro-pyrido[2,1-a]isoindol-6-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis

  摘要：

  The synthesis of a series of tricyclic antagonists for the prostaglandin D(2) receptor DP2 (CRTH2) is disclosed. The activities of the compounds were evaluated in a human DP2 binding assay and a human whole blood eosinophil shape change assay. Potential metabolic liabilities of the compounds were addressed through in vitro CYP studies. The lead compound was demonstrated to have efficacy in a mouse model of allergic rhinitis following oral dosing. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.085

文献信息

• TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Stearns Brian Andrew

  公开号：US20120004233A1

  公开（公告）日：2012-01-05

  Described herein are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了PGD2受体拮抗剂。还描述了包括本文所述化合物的制药组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症。
• [EN] TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D2 DE LA PROSTAGLANDINE
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2010085820A2

  公开（公告）日：2010-07-29

  Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
• Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis
  作者：Brian A. Stearns、Christopher Baccei、Gretchen Bain、Alex Broadhead、Ryan C. Clark、Heather Coate、Jilly F. Evans、Patrick Fagan、John H. Hutchinson、Christopher King、Catherine Lee、Daniel S. Lorrain、Peppi Prasit、Pat Prodanovich、Angelina Santini、Jill M. Scott、Nicholas S. Stock、Yen P. Truong

  DOI：10.1016/j.bmcl.2009.06.085

  日期：2009.8

  The synthesis of a series of tricyclic antagonists for the prostaglandin D(2) receptor DP2 (CRTH2) is disclosed. The activities of the compounds were evaluated in a human DP2 binding assay and a human whole blood eosinophil shape change assay. Potential metabolic liabilities of the compounds were addressed through in vitro CYP studies. The lead compound was demonstrated to have efficacy in a mouse model of allergic rhinitis following oral dosing. (C) 2009 Elsevier Ltd. All rights reserved.